Month: April 2020

On 21 April, AS LHV Group will disclose the renewed financial plan, taking into account effects of the corona virus outbreak and emergency situation on the economy. The financial plan will be announced at the same time as the 2020 Q1 interim report.LHV is organising an investor meeting, to introduce quarterly results and the financial plan. The meeting will be be conducted in the form of a webinar via video communication platform Zoom. Overview of results and the new financial plan will be given by Madis Toomsalu, CEO of LHV Group, Erki Kilu, CEO of LHV Pank, and Vahur Vallistu, CEO of LHV Varahaldus. The presentation will be made in Estonian.The virtual investor meeting will take place on 21 April at 9:00 a.m. We ask the interested investors to register via the link https://lhvbank.zoom.us/webinar/register/WN_JzDz7iVZQ0eE0grJLBlX_g....

21. aprillil avalikustab AS LHV Group uuendatud finantsplaani, mis võtab arvesse koroonaviiruse puhangu ja eriolukorra mõju majandusele. Finantsplaan avaldatakse samal ajal 2020. aasta I kvartali vahearuandega.Kvartalitulemuste ja uuendatud finantsplaani tutvustamiseks korraldab LHV Group investorkohtumise, mis seekord viiakse läbi vebinari vormis veebiseminaride keskkonna Zoom kaudu. Ülevaate tulemustest ja uuest finantsplaanist annavad ning osalejate küsimustele vastavad LHV Groupi juhataja Madis Toomsalu, LHV Panga juhatuse esimees Erki Kilu ja LHV Varahalduse juhatuse esimees Vahur Vallistu. Esitlus tehakse eesti keeles.Virtuaalne investorkohtumine toimub 21. aprillil kell 9.00. Enda osalemise registreerimiseks palume huvilistel kasutada linki https://lhvbank.zoom.us/webinar/register/WN_JzDz7iVZQ0eE0grJLBlX_g. Osalemiseks palume logida...

The Estonian Competition Authority has granted a permit for concentration of AS LHV Group and Toveko Invest OÜ for the companies to jointly enter the non-life insurance market.AS LHV Group and Toveko Invest OÜ plan to establish a non-life insurance undertaking called AS LHV Kindlustus, 65% of which would belong to AS LHV Group, and 35%, similarly to the ownership structure of AS LHV Finance, to Toveko Invest OÜ. The main business line for the undertaking would be offering non-life insurance products. The ensuing prerequisites for commencing the operations of the insurance undertaking include concluding an agreement between shareholders, establishing the company, and receiving an activity licence from the Financial Supervision Authority.LHV has disclosed the intent to establish an insurance undertaking in the 18 February market announcement:...

Konkurentsiamet andis loa AS-i LHV Group ja Toveko Invest OÜ koondumisele, et ettevõtted saaksid ühiselt sisenda kahjukindlustuse turule.AS LHV Group ja Toveko Invest OÜ plaanivad asutada kahjukindlustusseltsi ärinimega AS LHV Kindlustus, millest 65% kuuluks AS-ile LHV Group ja 35% sarnaselt AS-i LHV Finance omanikestruktuurile Toveko Invest OÜ-le. Seltsi põhitegevuseks saab kahjukindlustustoodete pakkumine. Kindlustusseltsi tegevusega alustamise järgnevateks eeldusteks on aktsionäridevahelise lepingu sõlmimine, ettevõtte asutamine ja tegevusloa saamine Finantsinspektsioonilt.LHV on teavitanud kavatsusest luua kindlustusselts 18. veebruari börsiteatega: https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=922262&messageId=1162156LHV Group on suurim kodumaine finantskontsern ja kapitali pakkuja Eestis. LHV Groupi...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, April 15, 2020 (GLOBE NEWSWIRE) — CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will open a new laboratory in Hamburg, Germany ─ acquiring the former laboratory facilities and equipment of Provecs Medical GmbH, a company formerly active in cancer immunotherapy. The new laboratory, which is opening in April 2020, will enable increased testing capacity for the COVID-19 virus and will also result in the expansion of laboratory capacity for the Company’s diagnostic testing of rare genetic diseases.Prof. Dr. Arndt Rolfs, CEO of the Company, stated, “The opening of our lab in Hamburg will...

ATHENS, Greece, April 15, 2020 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, today announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Uniper Global Commodities SE, Düsseldorf, for one of its Panamax dry bulk vessels, the m/v Calipso, for a period until minimum October 15, 2020 up to maximum December 31, 2020. The gross charter rate is US$4,750 per day for the first forty-five (45) days of the charter period and US$8,250 per day for the balance of the time charter, in each case minus a 5% commission paid to third parties. The charter commenced on April 13, 2020.The “Calipso” is a 73,691 dwt Panamax dry bulk vessel built in 2005.This employment is anticipated to generate approximately...

First Shipments of the COVID-19 Serological Test have been ReleasedHAUPPAUGE, N.Y., April 15, 2020 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced receipt of Emergency Use Authorization (EUA) for its DPP COVID-19 System. The DPP COVID-19 System is a serological point-of-care test and analyzer that provides numerical readings for both IgM and IgG levels within 15 minutes from a simple finger stick drop of blood. Both Chembio’s Micro Reader 1 and Micro Reader 2 analyzers are compatible with the test.“We are very pleased with the continued progress our teams are making to address the market demands with our DPP COVID-19 serological system,” stated Rick Eberly, Chembio’s Chief Executive Officer. “The flexibility of having two analyzers...

NEW YORK, April 15, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (“MSK”) and Massachusetts Institute of Technology (“MIT”) for a worldwide exclusive license and research collaboration to develop and commercialize antibody constructs based on the SADA-BiDE (2-step Self-Assembly and DisAssembly-Bispecific DOTA-Engaging antibody system) Pre-targeted Radioimmunotherapy Platform (the “SADA technology”), a concept also referred to as Liquid RadiationTM.                                          The SADA technology utilizes...

SILICON SLOPES, Utah, April 15, 2020 (GLOBE NEWSWIRE) — Domo (Nasdaq: DOMO), provider of the Domo Business Cloud, announced today that it has been named Business Intelligence Solution of the Year in the 2020 Data Breakthrough Awards. The Data Breakthrough Awards program, new this year, recognizes the most outstanding data technology solutions, services and companies.Winners of the Data Breakthrough Awards were chosen from more than 1,500 entries and were judged on six criteria: innovation, ease-of-use, functionality, performance, value and impact. Data Breakthrough is part of Tech Breakthrough, a market research and intelligence organization for technology leadership and innovation in today’s hottest and most competitive technology categories.“Now more than ever, companies need fast access to actionable data to stay informed and...

– Presentation with live audio webcast on Wednesday, April 22 at 1:30 PM ET, immediately followed by an interactive Q&A session –San Diego, California, April 15, 2020 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today that Michael Favish, CEO of Guardion Health Sciences, will present at the April 2020 Virtual Investor Summit on Wednesday, April 22nd, 2020 at 1:30 PM Eastern Time.A live audio webcast of the presentation will be available in the News and Events section of the Company’s website (guardionhealth.com). Immediately following the presentation, management...